4D Pharma PLC
LBPS
LBPS was delisted on the 24th of June, 2022.
8 hedge funds and large institutions have $430K invested in 4D Pharma PLC in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
20% less funds holding
Funds holding: 10 → 8 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
79% less capital invested
Capital invested by funds: $2.03M → $430K (-$1.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$5.57K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.78K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
-$483K |
| 2 |
Morgan Stanley
New York
|
-$133K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$57K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$13.1K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$11.5K |
LBPS Hedge Fund Activity: Q2 2022 in Review
8 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in 4D Pharma PLC (LBPS) for Q2 2022, worth a combined $430K — down 79% from $2.03M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LBPS and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was Credit Suisse, opening a new position worth an estimated $5.57K. The largest seller was Kepos Capital, exiting entirely with an estimated $483K sold.
- 8 institutional investors held 4D Pharma PLC (LBPS) as of Q2 2022, down from 10 in Q1 2022.
- Funds reported $430K of 4D Pharma PLC stock for Q2 2022, down 79% quarter-over-quarter.
- 1 fund opened new 4D Pharma PLC positions in Q2 2022 and 3 closed out, a net change of -2 holders.
- The largest 4D Pharma PLC buyer in Q2 2022 was Credit Suisse, an estimated $5.57K added.
- The largest 4D Pharma PLC seller in Q2 2022 was Kepos Capital, an estimated $483K sold.
Based on aggregated 13F filings for Q2 2022.